Related Experiment Video

Updated: May 24, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Fidaxomicin, a new treatment for Clostridium difficile infections

L Epstein1, Y Golan

  • 1Department of Medicine, Tufts Medical Center, Boston, MA, USA.

Drugs of Today (Barcelona, Spain : 1998)
|March 3, 2012
PubMed

Insights

Fidaxomicin offers an effective new treatment for Clostridium difficile infections (CDIs), showing comparable efficacy to vancomycin with a lower recurrence rate and minimal impact on gut microbiota.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Clostridium difficile is a leading cause of infectious diarrhea in the US.
  • Clostridium difficile infections (CDIs) pose a significant public health challenge.
  • Current treatment options for CDI have limitations, including recurrence and impact on gut flora.

Purpose of the Study:

  • To evaluate the efficacy and safety of fidaxomicin for treating Clostridium difficile infections (CDIs).
  • To compare fidaxomicin's effectiveness and recurrence rates against vancomycin.
  • To assess fidaxomicin's impact on the gut microbiome.

Main Methods:

  • In vitro studies assessing the spectrum of activity of fidaxomicin against C. difficile.
  • Clinical trials comparing fidaxomicin to vancomycin for CDI treatment.
  • Analysis of recurrence rates and adverse side effects in patients treated with fidaxomicin.

Main Results:

  • Fidaxomicin exhibits a narrow spectrum of activity, primarily targeting C. difficile.
  • Clinical trials demonstrate fidaxomicin is as effective as vancomycin in treating CDI.
  • Fidaxomicin treatment is associated with fewer recurrences compared to vancomycin.
  • Minimal systemic absorption and few adverse effects were observed with fidaxomicin.
  • Fidaxomicin has a limited impact on the gut flora.

Conclusions:

  • Fidaxomicin is a highly effective and safe new therapeutic option for Clostridium difficile infections (CDIs).
  • Its narrow spectrum of activity and favorable safety profile make it an attractive alternative to vancomycin.
  • Fidaxomicin's ability to reduce CDI recurrence and preserve gut microbiota is a significant clinical advantage.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...